Translocation (11;14)(q13;q32) and Preferential Involvement of Chromosomes 1, 2, 9, 13, and 17 in Mantle Cell Lymphoma

Espinet, Blanca; Solé, Françesc; Woessner, S; Bosch, Francesc; Florensa, Lourdes; Campo, Elı́as; Costa, Dolors; Lloveras, Elisabet; Vilà, R M; Besses, Carles; Montserrat, Emili; Sans-Sabrafén, J

doi:10.1016/s0165-4608(98)00228-3

Cited by 32 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple cytogenetic abnormalities in addition to the t(11;14) were identified in 22 (96%) cases in this study, as has been reported elsewhere (22)(23)(24). The most common additional abnormality involved chromosome 17, in 57% of cases.…”

Section: Discussionsupporting

confidence: 86%

Leukemic Mantle Cell Lymphoma: Clinical and Pathologic Spectrum of Twenty-Three Cases

et al. 2001

View full text Add to dashboard Cite

Twenty-three patients with marked leukemic involvement by mantle cell lymphoma (MCL) are described. Each patient had an absolute lymphocyte count more than 10 ؋ 10 9 /L. The diagnosis of MCL was supported by compatible immunophenotypic findings and the t(11;14)(q13;q32) in all cases. Morphologically, these cases exhibited a spectrum of findings that we divided into two groups using a cutoff of 20% large or blastoid cells (log rank test, P ‫؍‬ .004). Patients with small-cell (<20%) morphologic features survived longer than patients with large/blastoid (>20%) morphologic features, (P ‫؍‬ .003, log rank test). The most common additional karyotypic abnormality identified in this study involved chromosome 17, in 13 of 23 (56.5%) cases, which correlated with p53 overexpression but not with cytologic features. We conclude that cytologic features of MCL predict the prognosis of patients with marked leukemic involvement. Chromosome 17 abnormalities are common in leukemic MCL, may be involved in pathogenesis, and are associated with p53 expression.

show abstract

Section: Discussionsupporting

confidence: 86%

Leukemic Mantle Cell Lymphoma: Clinical and Pathologic Spectrum of Twenty-Three Cases

et al. 2001

View full text Add to dashboard Cite

show abstract

“…37 While it is well known that a translocation (t(11:14)) of PRAD-1/cyclin D1 and the IgH locus results in constitutive expression of this cell cycle regulator resulting in the pathology of the disease, 40,41 the stage at which this expression becomes critical is not yet clear. IgD ϩ CD38 Ϫ CD23 Ϫ CD71 ϩ cells may represent a stage in peripheral B-cell development when the initiation of large amounts of transcription of the IgH locus first occurs in the periphery.…”

Section: Discussionmentioning

confidence: 99%

A novel human B cell subpopulation representing the initial germinal center population to express AID

Kolar

Mehta

Pelayo

et al. 2006

Blood

View full text Add to dashboard Cite

“…20 Other cytogenetic alterations have been described at this locus in various types of tumor, such as additions, deletions and translocations, [43][44][45][46][47] meaning that these cytogenetic alterations could be related to tumorigenesis.…”

Section: Suz12 Overexpression Is Associated With Gene Locus Amplificamentioning

confidence: 99%

Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma

Martín-Pérez

Sanchez

Maestre

et al. 2010

The American Journal of Pathology

View full text Add to dashboard Cite

Polycomb proteins are known to be of great importance in human cancer pathogenesis. SUZ12 is a component of the Polycomb PRC2 complex that, along with EZH2, is involved in embryonic stem cell differentiation. EZH2 plays an essential role in many cancer types, but an equivalent involvement of SUZ12 has not been as thoroughly demonstrated. Here we show that SUZ12 is anomalously expressed in human primary tumors, especially in mantle cell lymphoma (MCL), pulmonary carcinomas and melanoma, and is associated with gene locus amplification in some cases. Using MCL as a model, functional and genomic studies demonstrate that SUZ12 loss compromises cell viability, increases apoptosis , and targets genes involved in central oncogenic pathways associated with MCL pathogenesis. Our results support the hypothesis that the abnormal expression of SUZ12 accounts for some of the unexplained features of MCL, such as abnormal DNA repair and increased resistance to apoptosis.

show abstract

Translocation (11;14)(q13;q32) and Preferential Involvement of Chromosomes 1, 2, 9, 13, and 17 in Mantle Cell Lymphoma

Cited by 32 publications

References 34 publications

Leukemic Mantle Cell Lymphoma: Clinical and Pathologic Spectrum of Twenty-Three Cases

Leukemic Mantle Cell Lymphoma: Clinical and Pathologic Spectrum of Twenty-Three Cases

A novel human B cell subpopulation representing the initial germinal center population to express AID

Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma

Contact Info

Product

Resources

About